CN116802209A - 半衰期延长部分及其使用方法 - Google Patents

半衰期延长部分及其使用方法 Download PDF

Info

Publication number
CN116802209A
CN116802209A CN202280012629.0A CN202280012629A CN116802209A CN 116802209 A CN116802209 A CN 116802209A CN 202280012629 A CN202280012629 A CN 202280012629A CN 116802209 A CN116802209 A CN 116802209A
Authority
CN
China
Prior art keywords
leu
gly
ser
ala
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280012629.0A
Other languages
English (en)
Chinese (zh)
Inventor
A·费兰特
J·G·豪雅
S·L·李
P·维尔迪诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN116802209A publication Critical patent/CN116802209A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Epoxy Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280012629.0A 2021-02-02 2022-02-01 半衰期延长部分及其使用方法 Pending CN116802209A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144696P 2021-02-02 2021-02-02
US63/144696 2021-02-02
PCT/US2022/014728 WO2022169757A1 (en) 2021-02-02 2022-02-01 Half-life extending moieties and methods of using the same

Publications (1)

Publication Number Publication Date
CN116802209A true CN116802209A (zh) 2023-09-22

Family

ID=80735776

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280012629.0A Pending CN116802209A (zh) 2021-02-02 2022-02-01 半衰期延长部分及其使用方法

Country Status (18)

Country Link
US (1) US20240316154A1 (cg-RX-API-DMAC10.html)
EP (1) EP4288452A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024506145A (cg-RX-API-DMAC10.html)
KR (1) KR20230137342A (cg-RX-API-DMAC10.html)
CN (1) CN116802209A (cg-RX-API-DMAC10.html)
AU (1) AU2022217754A1 (cg-RX-API-DMAC10.html)
CA (1) CA3204225A1 (cg-RX-API-DMAC10.html)
CL (2) CL2023002285A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023010002A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230366A (cg-RX-API-DMAC10.html)
DO (1) DOP2023000149A (cg-RX-API-DMAC10.html)
EC (1) ECSP23058246A (cg-RX-API-DMAC10.html)
IL (1) IL304219A (cg-RX-API-DMAC10.html)
JO (1) JOP20230173A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023009006A (cg-RX-API-DMAC10.html)
PE (1) PE20240233A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022169757A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202306754B (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260109751A1 (en) * 2022-12-30 2026-04-23 Eli Lilly And Company Methods of dulaglutide purification using hydrophobic interaction chromatography
EP4731669A2 (en) * 2023-06-21 2026-04-29 Eli Lilly and Company Compounds for the delivery of granulin across the blood brain barrier

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2259802A1 (en) * 2008-03-31 2010-12-15 Glaxo Group Limited Drug fusions and conjugates
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
AU2015231170B2 (en) * 2014-03-20 2019-10-03 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type III domains
WO2018104444A1 (en) * 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
EP3807311A4 (en) * 2018-04-24 2022-01-26 National Research Council of Canada SERUM ALBUM BINDING ANTIBODIES FOR TUNABLE HALF-LIFE OF BIOLOGICALS
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法

Also Published As

Publication number Publication date
PE20240233A1 (es) 2024-02-16
ECSP23058246A (es) 2023-09-29
CO2023010002A2 (es) 2023-09-08
JP2024506145A (ja) 2024-02-09
KR20230137342A (ko) 2023-10-04
CR20230366A (es) 2023-10-03
ZA202306754B (en) 2025-02-26
JOP20230173A1 (ar) 2023-07-30
CL2023002285A1 (es) 2024-02-23
AU2022217754A1 (en) 2023-07-27
DOP2023000149A (es) 2023-09-15
CA3204225A1 (en) 2022-08-11
EP4288452A1 (en) 2023-12-13
WO2022169757A1 (en) 2022-08-11
MX2023009006A (es) 2023-08-08
CL2025003008A1 (es) 2025-12-19
US20240316154A1 (en) 2024-09-26
IL304219A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
CN114174348B (zh) 胰岛素类似物及其使用方法
CN115109166B (zh) 一种治疗代谢疾病的多结构域活性蛋白
AU2010246108B2 (en) FGF21 mutants and uses thereof
CA2884730C (en) Fibronectin based scaffold domain proteins that bind to myostatin
JP7064618B2 (ja) 増殖分化因子１５アゴニスト化合物およびその使用方法
US10695404B2 (en) Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
CN109836503B (zh) 一种治疗代谢疾病的多重活性蛋白
JP2013518853A (ja) 血清アルブミンと結合することが可能なペプチド並びにこれを含む化合物、構築物及びポリペプチド
JP7465378B2 (ja) Ｈｉｖ融合体を標的とするポリペプチド
JP2016027801A (ja) 改良された抗血清アルブミン結合変異体
WO2022169757A1 (en) Half-life extending moieties and methods of using the same
EA048693B1 (ru) Фрагменты, увеличивающие период полужизни, и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination